AMIX · Autonomix Medical, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Factors raise substantial doubt about our ability to continue as a going concern”View the 10-K filed May 27, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-08-11 | Capelli Christopher |
Director |
Other↓
Filing footnotes — Option (Right to buy) (Direct)
Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation. |
Option (Right to buy)
|
3,750 |
| 2025-08-11 | KLEMP WALTER V |
Director, CEO and President |
Other↓
Filing footnotes — Option (Right to buy) (Direct)
Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation. Amount represents a revised share amount based on a 1-for-20 reverse stock split from October 25,2024. |
Option (Right to buy)
|
8,773 |
| 2025-08-11 | Hauser Bradley |
Chief Operating Officer |
Other↓
Filing footnotes — Option (Right to buy) (Direct)
Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received three months severance as consideration for the cancellation. |
Option (Right to buy)
|
45,000 |
| 2025-08-11 | Smith Trent N. |
CFO |
Other↓
Filing footnotes — Option (Right to buy) (Direct)
Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received an additional three months severance as consideration for the cancellation. |
Option (Right to buy)
|
11,405 |
| 2025-08-11 | Bisson Lori |
Director |
Other↓
Filing footnotes — Option (Right to buy) (Direct)
Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation. Amount represents a revised share amount based on a 1-for-20 reverse stock split from October 25,2024. |
Option (Right to buy)
|
46,680 |
| 2025-08-11 | Smith Trent N. |
CFO |
Other↓
Filing footnotes — Option (Right to buy) (Direct)
Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received an additional three months severance as consideration for the cancellation. Amount represents a revised share amount based on a 1-for-20 reverse stock split from October 25, 2024. |
Option (Right to buy)
|
21,250 |
| 2025-08-11 | Bisson Lori |
Director |
Other↓
Filing footnotes — Option (Right to buy) (Direct)
Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation. |
Option (Right to buy)
|
18,862 |
| 2024-06-21 | Bisson Lori |
Director |
Award↑
Filing footnotes — Option (Right to buy) (Direct)
Issued in connection with the reporting person's employment with the Company. The option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. |
Option (Right to buy)
|
377,221 |
| 2024-06-21 | Smith Trent N. |
CFO |
Award↑
Filing footnotes — Option (Right to buy) (Direct)
Issued in connection with the reporting person's employment with the Company The option set forth in this table vests in four annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. |
Option (Right to buy)
|
228,087 |
| 2024-06-21 | KLEMP WALTER V |
Director, CEO and President |
Award↑
Filing footnotes — Option (Right to buy) (Direct)
Issued in connection with the reporting person's employment with the Company The option set forth in this table vests in four annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. |
Option (Right to buy)
|
175,452 |
| 2024-06-18 | Robins David Andrew |
Director |
Buy↑
Filing footnotes — Warrant (Right to buy) (Indirect)
Includes a portion of 1,600,000 warrants to purchase shares of the Company's common stock that was held by Impulse Medical, Inc., in which Mr. Robins owns 19.5% through Portsmouth Therapeutics, Inc., an entity in which Mr. Robins also owns a 33.33% interest. The shares underlying the warrants are subject to a lockup agreement for a period of six months after January 29, 2024 with respect to 12.5% of the shares issued and twelve months after January 29, 2024 for the remainder of the shares. |
Warrant (Right to buy)
(I)
|
103,990 |
| 2024-06-18 | BioStar Ventures III, L.P. |
10% Owner |
Buy↑
Filing footnotes — Warrant to Purchase Common Stock (Direct)
The ability of the Reporting Person to exercise the warrants is subject to a beneficial ownership limitation initially set at 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of common stock issuable upon exercise of the warrants. This beneficial ownership limitation may be increased or decreased at the election of the holder, provided that the beneficial ownership limitation in no event exceeds 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise of the warrants and any increase shall not be effective until the 61st day after notice of adjustment is provided to the Issuer. |
Warrant to Purchase Common Stock
|
1,088,000 |
| 2024-06-17 | Hauser Bradley |
Chief Operating Officer |
Other↑
|
No Securities Owned
|
0 |
| 2024-06-17 | Hauser Bradley |
Chief Operating Officer |
Award↑
Filing footnotes — Option (Right to buy) (Direct)
Issued in connection with the reporting person's employment with the Company. The option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. |
Option (Right to buy)
|
900,000 |